Use of 64 Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study

The Journal of Nuclear Medicine

article

Joanne E. Mortimer¹  James R. Bading¹  Paul H. Frankel²  Mary I. Carroll¹  Yuan Yuan¹  Jinha M. Park³  Lusine Tumyan³  Nikita Gidwaney³  Erasmus K. Poku⁴  John E. Shively⁴  David M. Colcher⁴ 

[1] Department of Medical Oncology and Experimental Therapeutics;Department of Information Sciences;Department of Radiology;Department of Cancer Molecular Imaging and Therapy, Beckman Research Institute of the City of Hope

关键词: breast;    oncology;    PET;    breast cancer;    breast PET;   

DOI  :  10.2967/jnumed.121.262940

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

We hypothesized that functional imaging with 64Cu-DOTA-trastuzumab PET/CT would predict the response to the antibody–drug conjugate trastuzumab–emtansine (T-DM1). Methods: Ten women with metastatic human epidermal growth factor receptor 2–positive breast cancer underwent 18F-FDG PET/CT and 64Cu-DOTA-trastuzumab PET/CT on days 1 and 2 before treatment with T-DM1. Results: T-DM1–responsive patients had higher uptake than nonresponsive patients. Day 1 minimum SUVmax (5.6 vs. 2.8, P < 0.02), day 2 minimum SUVmax (8.1 vs. 3.2, P < 0.01), and day 2 average SUVmax (8.5 vs. 5.4, P < 0.05) for 64Cu-DOTA-trastuzumab all favored responding patients. Tumor-level response suggested threshold dependence on SUVmax. Patients with a day 2 minimum SUVmax above versus below the threshold had a median time to treatment failure of 28 mo versus 2 mo (P < 0.02). Conclusion: Measurement of trastuzumab uptake in tumors via PET/CT is promising for identifying patients with metastatic breast cancer who will benefit from T-DM1.

【 授权许可】

CC BY